BioLineRx Presents Data on BL-1040 at Cardiovascular
Revascularization Therapies Conference Demonstrating Potential to
Reduce Deterioration of Infarcted Heart Tissue and Maintain
Functionality
... JERUSALEM--(BUSINESS WIRE)--Mar 7, 2007 -
biolinerx Ltd.
(TASE:BLRX), Israel's leading drug developmen...ical Engineering at Ben-Gurion University.
About
biolinerx
BioLineRx, a clinical stage drug development com..., metabolic, infectious and autoimmune diseases.
biolinerx advances projects from early stage discovery and l...
BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming
Clinical Conferences
... JERUSALEM--(BUSINESS WIRE)--May 17, 2007 -
biolinerx Ltd. (TASE:
BLRX), Israel's leading drug developme... Faculty of Medicine, Tel Aviv
University.
About
biolinerx
BioLineRx, a clinical stage drug development com..., metabolic, infectious
and autoimmune diseases.
biolinerx advances projects from early stage discovery and l...
BioLineRx Presents Data From Successful Phase I Trial for BL-1020
in Schizophrenia at American Psychiatric Association Conference
... SAN DIEGO--(BUSINESS WIRE)--May 22, 2007 -
biolinerx Ltd.
(TASE:BLRX), Israel's leading drug developmen...dopamine
blockade which is indicative of efficacy.
biolinerx presented the
data in a poster (Abstract 235 XX) a... Faculty of Medicine, Tel Aviv
University.
About
biolinerx
BioLineRx, a clinical stage drug development com...
IKARIA(R) to In-License BioLineRx's BL-1040
..., July 6 /PRNewswire/ -- Ikaria Holdings, Inc. and
biolinerx Ltd. (TASE: BLRX) today announced that Ikaria has ... Scientist.
Under the terms of the agreement,
biolinerx will receive upfront and milestone payments.
biolinerx will also receive royalties on annual net sales. I...